Soothing and Re-epithelizing Activity of New Cosmetic Formulations in Comparison to Placebo and Untreated Control Area

Exclusion Criteria

• •Pregnancy (only for female subjects)
• •lactation (only for female subjects)
• •TEWL value on tested skin areas immediately after tape stripping \<15g/m2-h
• •change in the normal habits in the last month
• •participation in a similar study during the previous month
• •known allergy to one or several ingredients of the products on trial.
• •Dermatitis
• •presence of cutaneous disease on the tested area, as lesions, scars, malformations
• •clinical and significant skin condition on the test area.
• •Diabetes
• •endocrine disease
• •hepatic disorder
• •renal disorder
• •cardiac disorder
• •pulmonary disease
• •cancer
• •neurological or psychological disease
• •inflammatory/immunosuppressive disease
• •drug allergy.
• •Anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
• •using of drugs able to influence the test results in the investigator opinion.